A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 04 Jan 2018 Planned End Date changed from 5 May 2018 to 18 Jul 2018.
- 18 Oct 2017 Results from group A patients (n=20) presented at the 18th World Conference on Lung Cancer
- 05 Oct 2017 Planned End Date changed from 8 Sep 2018 to 5 May 2018.